Drug Profile

BCHBCH 10652

Alternative Names: dOTC

Latest Information Update: 16 Jan 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shire Pharmaceuticals Group
Developer Shire Pharmaceuticals Group; Wyeth
Class Antiretrovirals; Nucleosides; Small molecules
Mechanism of Action RNA-directed DNA polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued HIV infections

Most Recent Events

08 Jan 2019 Shire has been acquired and merged into Takeda
18 Aug 2000 A study in volunteers has been added to the adverse events and pharmacokinetics sections
05 May 2000 Discontinued-II for HIV infections treatment in USA (Unknown route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com